Search Results - "BROWN, Dean G"

Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone? by Brown, Dean G, Boström, Jonas

“…An analysis of chemical reactions used in current medicinal chemistry (2014), three decades ago (1984), and in natural product total synthesis has been…”
Get full text

Expanding the medicinal chemistry synthetic toolbox by Boström, Jonas, Brown, Dean G., Young, Robert J., Keserü, György M.

“…Analysis of the role of synthetic organic chemistry in the identification of chemical starting points for drug discovery and subsequent optimization into…”
Get full text

ESKAPEing the labyrinth of antibacterial discovery by Tommasi, Ruben, Brown, Dean G., Walkup, Grant K., Manchester, John I., Miller, Alita A.

“…Incentives are increasingly available for the development of new drugs to tackle antibiotic resistance, but major scientific challenges remain, such as…”
Get full text

Trends and Exceptions of Physical Properties on Antibacterial Activity for Gram-Positive and Gram-Negative Pathogens by Brown, Dean G, May-Dracka, Tricia L, Gagnon, Moriah M, Tommasi, Ruben

“…To better understand the difficulties surrounding the identification of novel antibacterial compounds from corporate screening collections, physical properties…”
Get full text

Impact of a five-dimensional framework on R&D productivity at AstraZeneca by Morgan, Paul, Brown, Dean G., Lennard, Simon, Anderton, Mark J., Barrett, J. Carl, Eriksson, Ulf, Fidock, Mark, Hamrén, Bengt, Johnson, Anthony, March, Ruth E., Matcham, James, Mettetal, Jerome, Nicholls, David J., Platz, Stefan, Rees, Steve, Snowden, Michael A., Pangalos, Menelas N.

“…In 2011, AstraZeneca set out to improve its research and development (R&D) productivity by focusing decision-making using a framework with five technical…”
Get full text

Prolonged tau clearance and stress vulnerability rescue by pharmacological activation of autophagy in tauopathy neurons by Silva, M. Catarina, Nandi, Ghata A., Tentarelli, Sharon, Gurrell, Ian K., Jamier, Tanguy, Lucente, Diane, Dickerson, Bradford C., Brown, Dean G., Brandon, Nicholas J., Haggarty, Stephen J.

“…Tauopathies are neurodegenerative diseases associated with accumulation of abnormal tau protein in the brain. Patient iPSC-derived neuronal cell models…”
Get full text

New natural products as new leads for antibacterial drug discovery by Brown, Dean G., Lister, Troy, May-Dracka, Tricia L.

“…Natural products have been a rich source of antibacterial drugs for many decades, but investments in this area have declined over the past two decades. The…”
Get full text

Clinical development times for innovative drugs by Brown, Dean G, Wobst, Heike J, Kapoor, Abhijeet, Kenna, Leslie A, Southall, Noel

Get full text

Novel Antibacterial Targets and Compounds Revealed by a High-Throughput Cell Wall Reporter Assay by Nayar, Asha S, Dougherty, Thomas J, Ferguson, Keith E, Granger, Brett A, McWilliams, Lisa, Stacey, Clare, Leach, Lindsey J, Narita, Shin-ichiro, Tokuda, Hajime, Miller, Alita A, Brown, Dean G, McLeod, Sarah M

“…A high-throughput phenotypic screen based on a Citrobacter freundii AmpC reporter expressed in Escherichia coli was executed to discover novel inhibitors of…”
Get full text

An Analysis of Successful Hit-to-Clinical Candidate Pairs by Brown, Dean G.

“…An analysis of 156 published clinical candidates from the Journal of Medicinal Chemistry between 2018 and 2021 was conducted to identify lead generation…”
Get full text

A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions by Brown, Dean G, Wobst, Heike J

“…A total of 378 novel drugs and 27 biosimilars approved by the U.S. Food and Drug Administration (FDA) between 2010 and 2019 were evaluated according to…”
Get full text

A Drug Discovery Perspective on FDA Expedited Development and Incentive Programs by Brown, Dean G.

“…Expedited development and approval pathways at the Food and Drug Administration (FDA) such as Priority review, Fast Track Designation, Breakthrough…”
Get full text

Adapting to the Changing Landscape of Biotech-Driven Drug Discovery by Brown, Dean G.

Get full text

Correction to “An Analysis of Successful Hit-to-Clinical Candidate Pairs” by Brown, Dean G.

Get full text

Where Do Recent Small Molecule Clinical Development Candidates Come From? by Brown, Dean G, Boström, Jonas

“…An analysis of 66 published clinical candidates from Journal of Medicinal Chemistry has been conducted to shed light on which lead generation strategies are…”
Get full text

Tool inhibitors and assays to interrogate the biology of the TRAF2 and NCK interacting kinase by Read, Jon, Collie, Iain T., Nguyen-McCarty, Michelle, Lucaj, Christopher, Robinson, James, Conway, Leslie, Mukherjee, Jayanta, McCall, Eileen, Donohoe, Gerard, Flavell, Elizabeth, Peciak, Karolina, Warwicker, Juli, Dix, Carly, Van den Hoven, Bernard G., Madin, Andrew, Brown, Dean G., Moss, Stephen, Haggarty, Stephen J., Brandon, Nicholas J., Bürli, Roland W.

“…[Display omitted] The TRAF2 and NCK interacting kinase (TNIK) has been proposed to play a role in cytoskeletal organization and synaptic plasticity and has…”
Get full text

Axl receptor tyrosine kinase is a regulator of apolipoprotein E by Zhao, Wenchen, Fan, Jianjia, Kulic, Iva, Koh, Cheryl, Clark, Amanda, Meuller, Johan, Engkvist, Ola, Barichievy, Samantha, Raynoschek, Carina, Hicks, Ryan, Maresca, Marcello, Wang, Qi, Brown, Dean G, Lok, Alvin, Parro, Cameron, Robert, Jerome, Chou, Hsien-Ya, Zuhl, Andrea M, Wood, Michael W, Brandon, Nicholas J, Wellington, Cheryl L

“…Alzheimer's disease (AD), the leading cause of dementia, is a chronic neurodegenerative disease. Apolipoprotein E (apoE), which carries lipids in the brain in…”
Get full text

In Vitro Metabolism Studies of Nomifensine Monooxygenation Pathways: Metabolite Identification, Reaction Phenotyping, and Bioactivation Mechanism by JIAN YU, BROWN, Dean G, BURDETTE, Doug

“…Multiple GSH adducts of the oxidative products of nomifensine (M1-M9) in human hepatocytes and liver microsomes have been identified recently. The current…”
Get full text

Protease-activated receptor-2 ligands reveal orthosteric and allosteric mechanisms of receptor inhibition by Kennedy, Amanda J., Sundström, Linda, Geschwindner, Stefan, Poon, Eunice K. Y., Jiang, Yuhong, Chen, Rongfeng, Cooke, Rob, Johnstone, Shawn, Madin, Andrew, Lim, Junxian, Liu, Qingqi, Lohman, Rink-Jan, Nordqvist, Anneli, Fridén-Saxin, Maria, Yang, Wenzhen, Brown, Dean G., Fairlie, David P., Dekker, Niek

“…Protease-activated receptor-2 (PAR2) has been implicated in multiple pathophysiologies but drug discovery is challenging due to low small molecule tractability…”
Get full text

Drug discovery strategies to outer membrane targets in Gram-negative pathogens by Brown, Dean G.

“…This review article summarizes important chemical and structural advances in Gram-negative outer membrane targets within the key pathways of…”
Get full text